Fibroblast growth factor 23 (FGF23) gene polymorphism in children with Kawasaki syndrome (KS) and susceptibility to cardiac abnormalities

Italian Journal of Pediatrics

Volumn 39, Issue 1, 2013, Pages

  Falcini, Fernanda ^a   Rigante, Donato ^b   Masi, Laura ^a   Covino, Marcello ^b   Franceschelli, Francesco ^a   Leoncini, Gigliola ^a   Tarantino, Giusyda ^b   Matucci Cerinic, Marco ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cardiac abnormalities; Child; Fibroblast growth factor 23; Kawasaki syndrome

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FIBRINOGEN; FIBROBLAST GROWTH FACTOR 23; GENOMIC DNA; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; FEVER; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NUCLEOTIDE SEQUENCE; ONSET AGE; PERICARDIAL EFFUSION; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; WILD TYPE;

AGE DISTRIBUTION; ANALYSIS OF VARIANCE; CHILD, PRESCHOOL; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FIBROBLAST GROWTH FACTORS; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HEART DEFECTS, CONGENITAL; HUMANS; INCIDENCE; INFANT; ITALY; LOGISTIC MODELS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC;

EID: 84886398918     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-39-69     Document Type: Article

References (9)

1. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rigante D, Valentini P, Rizzo D, et al. Rheumatol Int 2010 30 841 846 10.1007/s00296-009-1337-1 20049445
2. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Falcini F, Capannini S, Rigante D, Pediatr Rheumatol Online J 2011 9 17 10.1186/1546-0096-9-17 21774801
3. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Yu X, Ibrahimi O, Goetz R, et al. Endocrinology 2005 146 4647 4656 10.1210/en.2005-0670 16081635 (Pubitemid 41446602)
4. The fibroblast growth factor 23: a new player in the field of cardiovascular, bone and renal disease. Cozzolino M, Mazzaferro S, Curr Vasc Pharmacol 2010 8 404 411 10.2174/157016110791112313 20180772
5. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. De Rosa G, Pardeo M, Rigante D, Eur Rev Med Pharmacol Sci 2007 11 301 308 18074939 (Pubitemid 350200347)
6. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. Dai B, David V, Martin A, et al. PLos One 2012 7 44161 10.1371/journal.pone.0044161 22970174
7. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Endo I, Fukumoto S, Ozono K, et al. Bone 2008 42 1235 1239 10.1016/j.bone.2008.02.014 18396126
8. Fibroblast growth factor 23 and the heart. Faul C, Curr Opin Nephrol Hypertens 2012 21 369 375 10.1097/MNH.0b013e32835422c4 22531163
9. Can fibroblast growth factor (FGF)-23 circulating levels suggest coronary artery abnormalities in children with Kawasaki disease? Masi L, Franceschelli F, Leoncini G, et al. Clin Exper Rheumatol 2013 31 149 153